Mark Shackleton

Prof. Mark Shackleton

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Annals of Oncology
Verified
Journal Article
Closed access
LTL. Tan
L. Tan
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu
RLRebecca Lee
Rebecca Lee
JLJ. Li
J. Li
JCJ. Callahan
J. Callahan
SDS.-J. Dawson
S.-J. Dawson
The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma. Somatic mutations were identified in 99/133 (74%) patients through tumor tissue sequencing. Personalized droplet digital PCR (ddPCR) assays were used to detect known mutations in 315 prospectively collected plasma samples from mutation-positive patients. External validation was performed in a prospective independent cohort (n = 29). ctDNA was detected in 37 of 99 (37%) individuals. In 81 patients who did not receive adjuvant therapy, 90% of patients with ctDNA detected at baseline and 100% of patients with ctDNA detected at the postoperative timepoint relapsed at a median follow up of 20 months. ctDNA detection predicted patients at high risk of relapse at baseline [relapse-free survival (RFS) hazard ratio (HR) 2.9; 95% confidence interval (CI) 1.5-5.6; P = 0.002] and postoperatively (HR 10; 95% CI 4.3-24; P < 0.001). ctDNA detection at baseline [HR 2.9; 95% CI 1.3-5.7; P = 0.003 and postoperatively (HR 11; 95% CI 4.3-27; P < 0.001] was also associated with inferior distant metastasis-free survival (DMFS). These findings were validated in the independent cohort. ctDNA detection remained an independent predictor of RFS and DMFS in multivariate analyses after adjustment for disease stage and BRAF mutation status. Baseline and postoperative ctDNA detection in two independent prospective cohorts identified stage III melanoma patients at highest risk of relapse and has potential to inform adjuvant therapy decisions.

19 June 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
XZXiaomeng Zhang
Xiaomeng Zhang
LYLie Yang
Lie Yang
PSPacman Szeto
Pacman Szeto
GAGamze Kuser Abali
Gamze Kuser Abali
YZYoufang Zhang
Youfang Zhang
KHKieran F. Harvey
Kieran F. Harvey

12 September 2016 in Nature Biotechnology
Verified
Journal Article
Closed access
TPThe Melbourne Melanoma Project
The Melbourne Melanoma Project
KAKathryn Alsop
Kathryn Alsop
T(the Australian Ovarian Cancer Study Group (AOCS)
the Australian Ovarian Cancer Study Group (AOCS)
T(the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
HTHeather Thorne
Heather Thorne
DBDavid D Bowtell
David D Bowtell

4 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IVIsmael A. Vergara
Ismael A. Vergara
CMChristopher P. Mintoff
Christopher P. Mintoff
SSShahneen Sandhu
Shahneen Sandhu
LMLachlan McIntosh
Lachlan McIntosh
RYRichard J. Young
Richard J. Young
MSMark Shackleton
Mark Shackleton
Although melanoma is initiated by acquisition of point mutations and limited focal copy number alterations in melanocytes-of-origin, the nature of genetic changes that characterise lethal metastatic disease is poorly understood. Here, we analyze the evolution of human melanoma progressing from early to late disease in 13 patients by sampling their tumours at multiple sites and times. Whole exome and genome sequencing data from 88 tumour samples reveals only limited gain of point mutations generally, with net mutational loss in some metastases. In contrast, melanoma evolution is dominated by whole genome doubling and large-scale aneuploidy, in which widespread loss of heterozygosity sculpts the burden of point mutations, neoantigens and structural variants even in treatment-naïve and primary cutaneous melanomas in some patients. These results imply that dysregulation of genomic integrity is a key driver of selective clonal advantage during melanoma progression.

22 August 2016 in Nature Communications
Verified
Journal Article
Open access
UEUgur Eskiocak
Ugur Eskiocak
VRVijayashree Ramesh
Vijayashree Ramesh
JGJennifer G. Gill
Jennifer G. Gill
ZZZhiyu Zhao
Zhiyu Zhao
SYStacy W. Yuan
Stacy W. Yuan
SMSean J. Morrison
Sean J. Morrison
New therapies are required for melanoma. Here, we report that multiple cardiac glycosides, including digitoxin and digoxin, are significantly more toxic to human melanoma cells than normal human cells. This reflects on-target inhibition of the ATP1A1 Na+/K+ pump, which is highly expressed by melanoma. MEK inhibitor and/or BRAF inhibitor additively or synergistically combined with digitoxin to induce cell death, inhibiting growth of patient-derived melanomas in NSG mice and synergistically extending survival. MEK inhibitor and digitoxin do not induce cell death in human melanocytes or haematopoietic cells in NSG mice. In melanoma, MEK inhibitor reduces ERK phosphorylation, while digitoxin disrupts ion gradients, altering plasma membrane and mitochondrial membrane potentials. MEK inhibitor and digitoxin together cause intracellular acidification, mitochondrial calcium dysregulation and ATP depletion in melanoma cells but not in normal cells. The disruption of ion homoeostasis in cancer cells can thus synergize with targeted agents to promote tumour regression in vivo.

12 April 2018 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JLJ. Lewin
J. Lewin
LSL. Sayers
L. Sayers
DKD. Kee
D. Kee
IWI. Walpole
I. Walpole
ASA. Sanelli
A. Sanelli
MSMark Shackleton
Mark Shackleton
As early detection of recurrent melanoma maximizes treatment options, patients usually undergo post-operative imaging surveillance, increasingly with FDG-PET/CT (PET). To assess this, we evaluated stage 3 melanoma patients who underwent prospectively applied and sub-stage-specific schedules of PET surveillance. From 2009, patients with stage 3 melanoma routinely underwent PET +/− MRI brain scans via defined schedules based on sub-stage-specific relapse probabilities. Data were collected regarding patient characteristics and outcomes. Contingency analyses were carried out of imaging outcomes. One hundred and seventy patients (stage 3A: 34; 3B: 93; 3C: 43) underwent radiological surveillance. Relapses were identified in 65 (38%) patients, of which 45 (69%) were asymptomatic. False-positive imaging findings occurred in 7%, and 6% had treatable second (non-melanoma) malignancies. Positive predictive values (PPV) of individual scans were 56%−83%. Negative scans had predictive values of 89%−96% for true non-recurrence [negative predictive values (NPV)] until the next scan. A negative PET at 18 months had NPVs of 80%−84% for true non-recurrence at any time in the 47-month (median) follow-up period. Sensitivity and specificity of the overall approach of sub-stage-specific PET surveillance were 70% and 87%, respectively. Of relapsed patients, 33 (52%) underwent potentially curative resection and 10 (16%) remained disease-free after 24 months (median). Application of sub-stage-specific PET in stage 3 melanoma enables asymptomatic detection of most recurrences, has high NPVs that may provide patient reassurance, and is associated with a high rate of detection of resectable and potentially curable disease at relapse.